Announcements
- Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
- Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
- Idorsia announces changes to Idorsia Executive Committee and Board of Directors
- Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
- Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
- Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
- Bondholders approve amended terms of the 2024 convertible bonds
- Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
- Idorsia publishes an invitation to a bondholder meeting
More ▼
Key statistics
On Friday, Idorsia Ltd (0RQE:LSE) closed at 2.59, 100.08% above the 52 week low of 1.29 set on Jan 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.55 |
---|---|
High | -- |
Low | -- |
Bid | 2.45 |
Offer | 2.71 |
Previous close | 2.54 |
Average volume | 7.04k |
---|---|
Shares outstanding | 188.97m |
Free float | 120.68m |
P/E (TTM) | -- |
Market cap | 490.18m CHF |
EPS (TTM) | -0.3534 CHF |
Data delayed at least 20 minutes, as of May 31 2024 13:15 BST.
More ▼